Melatonin Supplementation Improves Glycemic Control in Type 2 Diabetes, Research Finds

For this purpose, the researchers conducted a comprehensive search of PubMed/Medline, Scopus, and Web of Science until July 2024 to identify eligible randomized clinical trials (RCTs). They estimated overall effect sizes using a random-effects model, presenting the results as weighted mean differences (WMD). Additionally, the heterogeneity among the included trials was evaluated using the Cochran Q test, with interpretations based on the I² statistic.

The research revealed the following findings:

• Out of 1,361 papers reviewed, eight eligible RCTs were included in this meta-analysis.
• The results revealed that melatonin supplementation significantly reduced fasting blood glucose (WMD = -12.65 mg/dl), insulin levels (WMD = -2.30 μU/ml), hemoglobin A1c (WMD = -0.79%), and HOMA-IR (WMD = -0.83).

This systematic review and meta-analysis indicate that melatonin supplementation may provide significant benefits for glycemic control in individuals with Type 2 diabetes, especially at higher doses and over longer durations.

"As awareness of personalized treatment strategies in diabetes care increases, melatonin could become a valuable adjunct therapy. However, further research involving larger sample sizes is essential to establish definitive conclusions," the researchers concluded.

Reference:

Abadi, Reza Nejad Shahrokh, et al. "Impact of Melatonin Supplementation On Glycemic Parameters in Patients With Type 2 Diabetes: a Systematic Review and Meta-analysis." Current Pharmaceutical Design, 2024.